Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > with TLT at 2.5% the value of phase 1 LSD play MMED...
View:
Post by SouthernTierTom on Jun 23, 2021 1:10pm

with TLT at 2.5% the value of phase 1 LSD play MMED...

Is it wise to slap a 100M prospectus for the "market" to consider?

I don't understand the "logic"??

We have a FDA FASTTRACK and a valuation of 50M CAD vs. the LSD comapny at 2BILLION CAD

What is wrong and what are we doing to rectify the poor market cap?

In fareness...they do have ecstacy and now mescaline studies too as far as I know....but does that really allow us to be worth 2.5% their value?
Comment by SouthernTierTom on Jun 23, 2021 2:04pm
WHAT possible benefit could there be to this unusual "lack of value"? Is it wise to slap a 100M prospectus for the "market" to consider? I don't understand the "logic"?? We have a FDA FASTTRACK and a valuation of 50M CAD vs. the LSD comapny at 2BILLION CAD What is wrong and what are we doing to rectify the poor market cap? In fareness...they do have ecstacy ...more  
Comment by SouthernTierTom on Jun 23, 2021 7:13pm
Concerning that the regulars here don't have questions around the valuation drought... You know "fellas"...when "money" is required, it tends to get done based on current valuations.. Lest we forget the 55 cent bullboard hype and subsequent 30 cent financing with a 35 cent sidecar....followed of course by 12.7M options at 25 pennies CAD. INBOX me for further private ...more  
Comment by SouthernTierTom on Jun 24, 2021 12:12pm
ANYONE had time to consider the perplexing valuation? Concerning that the regulars here don't have questions around the valuation drought... You know "fellas"...when "money" is required, it tends to get done based on current valuations.. Lest we forget the 55 cent bullboard hype and subsequent 30 cent financing with a 35 cent sidecar....followed of course by 12.7M ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250